Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
| Patient | Anti-PD1 Therapy | Duration of Immunotherapy (weeks) | Progression of Disease | Time to Progression (weeks) |
|---|---|---|---|---|
| 1 | Continued | 10 | Yes | 16 |
| 2 | Continued | 20.6 | Yes | 21 |
| 3 | Held1 | 53.1 | Yes | N/A2 |
| 4 | Discontinued | 0 | No | - |
| 5 | Discontinued | 0 | Yes | 64 |
1Patient was switched from nivolumab to atezolizumab after immunotherapy was held for 9 months following DKA occurrence. 2Patient with disease progression prior to DKA.
